Literature DB >> 34318581

MRI-TRUS registration methodology for TRUS-guided HDR prostate brachytherapy.

Philip McGeachy1,2,3, Elizabeth Watt1,2, Siraj Husain2,4, Kevin Martell2,4, Pedro Martinez1,3, Summit Sawhney5, Kundan Thind1,2,3.   

Abstract

PURPOSE: High-dose-rate (HDR) prostate brachytherapy is an established technique for whole-gland treatment. For transrectal ultrasound (TRUS)-guided HDR prostate brachytherapy, image fusion with a magnetic resonance image (MRI) can be performed to make use of its soft-tissue contrast. The MIM treatment planning system has recently introduced image registration specifically for HDR prostate brachytherapy and has incorporated a Predictive Fusion workflow, which allows clinicians to attempt to compensate for differences in patient positioning between imaging modalities. In this study, we investigate the accuracy of the MIM algorithms for MRI-TRUS fusion, including the Predictive Fusion workflow.
MATERIALS AND METHODS: A radiation oncologist contoured the prostate gland on both TRUS and MRI. Four registration methodologies to fuse the MRI and the TRUS images were considered: rigid registration (RR), contour-based (CB) deformable registration, Predictive Fusion followed by RR (pfRR), and Predictive Fusion followed by CB deformable registration (pfCB). Registrations were compared using the mean distance to agreement and the Dice similarity coefficient for the prostate as contoured on TRUS and the registered MRI prostate contour.
RESULTS: Twenty patients treated with HDR prostate brachytherapy at our center were included in this retrospective evaluation. For the cohort, mean distance to agreement was 2.1 ± 0.8 mm, 0.60 ± 0.08 mm, 2.0 ± 0.5 mm, and 0.59 ± 0.06 mm for RR, CB, pfRR, and pfCB, respectively. Dice similarity coefficients were 0.80 ± 0.05, 0.93 ± 0.02, 0.81 ± 0.03, and 0.93 ± 0.01 for RR, CB, pfRR, and pfCB, respectively. The inclusion of the Predictive Fusion workflow did not significantly improve the quality of the registration.
CONCLUSIONS: The CB deformable registration algorithm in the MIM treatment planning system yielded the best geometric registration indices. MIM offers a commercial platform allowing for easier access and integration into clinical departments with the potential to play an integral role in future focal therapy applications for prostate cancer.
© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Entities:  

Keywords:  HDR brachytherapy, MIM, MRI, prostate cancer, registration, TRUS

Year:  2021        PMID: 34318581     DOI: 10.1002/acm2.13292

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


  1 in total

1.  Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 2: in-vivo tumor-targeting using a classification model combining spectral and MRI-radiomics features.

Authors:  David Orlando Grajales Lopera; Fabien Picot; Roozbeh Shams; Frédérick Dallaire; Guillaume Sheehy; Stephanie Alley; Maroie Barkati; Guila Delouya; Jean-Francois Carrier; Mirela Birlea; Dominique Trudel; Frédéric Leblond; Cynthia Ménard; Samuel Kadoury
Journal:  J Biomed Opt       Date:  2022-09       Impact factor: 3.758

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.